Dr Reddy's completes acquisition of betapharm
Emerging global pharmaceutical company Dr Reddy's Laboratories, based in India, has completed the acquisition of 100% of betapharm Group, the fourth-largest generic pharmaceuticals company in Germany, for a total enterprise value of €480m in cash.
Emerging global pharmaceutical company Dr Reddy's Laboratories, based in India, has completed the acquisition of 100% of betapharm Group, the fourth-largest generic pharmaceuticals company in Germany, for a total enterprise value of €480m in cash.
'The strategic investment in betapharm is a step forward towards realising Dr Reddy's strategic intention of building a global generics business with strategic presence in all key markets,' said Satish Reddy, chief operating officer, Dr Reddy's Laboratories.